DOCSLIB.ORG

GENVOYA Is Contraindicated with Drugs That: GENVOYA Safely and Effectively

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GENVOYA Is Contraindicated with Drugs That: GENVOYA Safely and Effectively HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------CONTRAINDICATIONS------------------------------- These highlights do not include all the information needed to use Coadministration of GENVOYA is contraindicated with drugs that: GENVOYA safely and effectively. See full prescribing information • Are highly dependent on CYP3A for clearance and for which for GENVOYA. elevated plasma concentrations are associated with serious adverse events. (4) GENVOYA® (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use • Strongly induce CYP3A, which may lead to lower exposure of one or Initial U.S. Approval: 2015 more components and loss of efficacy of GENVOYA and possible resistance. (4) WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B -----------------------WARNINGS AND PRECAUTIONS------------------------ See full prescribing information for complete boxed warning. • Risk of adverse reactions or loss of virologic response due to drug interactions: The concomitant use of GENVOYA and other drugs Severe acute exacerbations of hepatitis B have been may result in known or potentially significant drug interactions, some reported in patients who are coinfected with HIV-1 and HBV of which may lead to loss of therapeutic effect of GENVOYA and and have discontinued products containing emtricitabine possible development of resistance; clinically significant adverse and/or tenofovir disoproxil fumarate (TDF), and may occur reactions from greater exposures of concomitant drugs; or loss of with discontinuation of GENVOYA. Hepatic function should therapeutic effect of concomitant drugs. (5.2) be monitored closely in these patients. If appropriate, anti- • Immune reconstitution syndrome: May necessitate further evaluation hepatitis B therapy may be warranted. (5.1) and treatment. (5.3) • New onset or worsening renal impairment: Assess serum creatinine, ---------------------------RECENT MAJOR CHANGES--------------------------- estimated creatinine clearance, urine glucose and urine protein Warnings and Precautions, Risk of Adverse Reactions or when initiating GENVOYA and during therapy on a clinically Loss of Virologic Response Due to Drug Interactions (5.2) 12/2020 appropriate schedule in all patients. Also assess serum phosphorus Warnings and Precautions, Immune Reconstitution in patients with chronic kidney disease. (5.4) Syndrome (5.3) 12/2020 • Lactic acidosis/severe hepatomegaly with steatosis: Discontinue Warnings and Precautions, New Onset or Worsening Renal treatment in patients who develop symptoms or laboratory findings Impairment (5.4) 03/2021 suggestive of lactic acidosis or pronounced hepatotoxicity. (5.5) ----------------------------INDICATIONS AND USAGE---------------------------- -------------------------------ADVERSE REACTIONS------------------------------ GENVOYA is a four-drug combination of elvitegravir, an HIV-1 Most common adverse reaction (incidence greater than or equal to integrase strand transfer inhibitor (INSTI), cobicistat, a CYP3A 10%, all grades) is nausea. (6.1) inhibitor, and emtricitabine and tenofovir alafenamide (TAF), both HIV- 1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and To report SUSPECTED ADVERSE REACTIONS, contact Gilead is indicated as a complete regimen for the treatment of HIV-1 infection Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or in adults and pediatric patients weighing at least 25 kg who have no www.fda.gov/medwatch. antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less -------------------------------DRUG INTERACTIONS------------------------------- than 50 copies per mL) on a stable antiretroviral regimen for at least 6 GENVOYA should not be administered with other antiretroviral months with no history of treatment failure and no known substitutions • medications for treatment of HIV-1 infection. (7.1) associated with resistance to the individual components of GENVOYA. (1) • GENVOYA can alter the concentration of drugs metabolized by CYP3A or CYP2D6. Drugs that induce CYP3A can alter the ------------------------DOSAGE AND ADMINISTRATION----------------------- concentrations of one or more components of GENVOYA. Consult • Testing: Prior to or when initiating GENVOYA test for hepatitis B the full prescribing information prior to and during treatment for virus infection. Prior to or when initiating GENVOYA, and during potential drug-drug interactions. (4, 7.2, 7.3, 12.3) treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine ------------------------USE IN SPECIFIC POPULATIONS----------------------- protein in all patients. In patients with chronic kidney disease, also • Pregnancy: Not recommended for use during pregnancy because of assess serum phosphorus. (2.1) substantially lower exposures of cobicistat and elvitegravir during • Recommended dosage: One tablet taken orally once daily with food pregnancy. GENVOYA should not be initiated in pregnant in patients with body weight at least 25 kg and a creatinine individuals. (2.5, 8.1) clearance greater than or equal to 30 mL per minute, or in adult • Lactation: Breastfeeding is not recommended due to the potential patients with creatinine clearance less than 15 mL per minute who for HIV transmission. (8.2) are receiving chronic hemodialysis. On days of hemodialysis, • Pediatrics: Not recommended for patients weighing less than 25 kg. administer GENVOYA after hemodialysis. (2.2) (8.4) • Renal impairment: GENVOYA is not recommended in patients with estimated creatinine clearance of 15 to below 30 mL per minute, or See 17 for PATIENT COUNSELING INFORMATION and below 15 mL per minute who are not receiving chronic hemodialysis. FDA-approved patient labeling. (2.3) • Hepatic impairment: GENVOYA is not recommended in patients Revised: 09/2021 with severe hepatic impairment. (2.4) ----------------------DOSAGE FORMS AND STRENGTHS--------------------- Tablets: 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide. (3) Gilead Sciences 1 FULL PRESCRIBING INFORMATION: CONTENTS* 8 USE IN SPECIFIC POPULATIONS WARNING: POST TREATMENT ACUTE EXACERBATION OF 8.1 Pregnancy HEPATITIS B 8.2 Lactation 1 INDICATIONS AND USAGE 8.4 Pediatric Use 2 DOSAGE AND ADMINISTRATION 8.5 Geriatric Use 2.1 Testing When Initiating and During Treatment with GENVOYA 8.6 Renal Impairment 2.2 Recommended Dosage 8.7 Hepatic Impairment 2.3 Not Recommended in Patients with Severe Renal Impairment 10 OVERDOSAGE 2.4 Not Recommended in Patients with Severe Hepatic Impairment 11 DESCRIPTION 2.5 Not Recommended During Pregnancy 12 CLINICAL PHARMACOLOGY 3 DOSAGE FORMS AND STRENGTHS 12.1 Mechanism of Action 4 CONTRAINDICATIONS 12.2 Pharmacodynamics 5 WARNINGS AND PRECAUTIONS 12.3 Pharmacokinetics 5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected 12.4 Microbiology with HIV-1 and HBV 13 NONCLINICAL TOXICOLOGY 5.2 Risk of Adverse Reactions or Loss of Virologic Response Due to 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Drug Interactions 5.3 Immune Reconstitution Syndrome 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 5.4 New Onset or Worsening Renal Impairment 14.1 Description of Clinical Trials 5.5 Lactic Acidosis/Severe Hepatomegaly with Steatosis 6 ADVERSE REACTIONS 14.2 Clinical Trial Results in HIV-1 Treatment-Naïve Subjects 14.3 Clinical Trial Results in HIV-1 Virologically-Suppressed 6.1 Clinical Trials Experience Subjects Who Switched to GENVOYA 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 14.4 Clinical Trial Results in HIV-1 Infected Subjects with Renal Impairment 7.1 Not Recommended with Other Antiretroviral Medications 14.5 Clinical Trial Results in HIV-1 Infected Pediatric Subjects 7.2 Potential for GENVOYA to Affect Other Drugs 7.3 Potential for Other Drugs to Affect One or More Components of Between the Ages of 6 to Less than 18 GENVOYA 16 HOW SUPPLIED/STORAGE AND HANDLING 7.4 Drugs Affecting Renal Function 17 PATIENT COUNSELING INFORMATION 7.5 Established and Other Potentially Significant Interactions 7.6 Drugs without Clinically Significant Interactions with GENVOYA * Sections or subsections omitted from the full prescribing information are not listed. Gilead Sciences 2 FULL PRESCRIBING INFORMATION WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue GENVOYA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)]. 1 INDICATIONS AND USAGE GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA [see Clinical Studies (14)].
Load more

Recommended publications
  • Page: Treatment-Drugs
    © National HIV Curriculum PDF created September 29, 2021, 5:12 am Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine (Symtuza) Table of Contents Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza Summary Drug Summary Key Clinical Trials Key Drug Interactions Drug Summary The fixed-dose combination tablet darunavir-cobicistat-tenofovir alafenamide-emtricitabine is a single-tablet regimen that can be considered for treatment-naïve or certain treatment-experienced adults living with HIV. This single-tablet regimen offers a one pill daily regimen with high barrier to resistance (due to the darunavir- cobicistat), with potentially less renal and bone toxicity as compared to regimens that include tenofovir DF; however, it has potential gastrointestinal adverse effects and drug-drug interactions, primarily due to the cobicistat component. In clinical trials, darunavir-cobicistat-tenofovir alafenamide-emtricitabine was compared to darunavir-cobicistat plus tenofovir DF-emtricitabine as initial therapy for treatment-naïve individuals and found to be equally effective in terms of viral suppression. A switch to the fixed-dose combination tablet was also compared to continuing a boosted protease inhibitor plus tenofovir DF- emtricitabine and again determined to have equivalent efficacy. The FDA has approved darunavir-cobicistat- tenofovir alafenamide-emtricitabine as a complete regimen for treatment-naïve individuals or treatment- experienced individuals who have a suppressed HIV RNA level on a stable regimen for at least 6 months and no resistance to darunavir or tenofovir. Key Clinical Trials A phase 3 trial in treatment-naïve individuals compared the fixed-dose single-tablet regimen darunavir- cobicistat-tenofovir alafenamide-emtricitabine with the regimen darunavir-cobicistat plus tenofovir DF- emtricitabine emtricitabine [AMBER].
    [Show full text]
  • Product Monograph for CELSENTRI
    PRODUCT MONOGRAPH PrCELSENTRI maraviroc Tablets 150 and 300 mg CCR5 antagonist ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: July 05, 2019 Submission Control No: 226222 © 2019 ViiV Healthcare group of companies or its licensor. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 60 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION..............................................................................28 OVERDOSAGE ................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ............................................................31 STORAGE AND STABILITY..........................................................................................36
    [Show full text]
  • PATIENT INFORMATION STRIBILD® (STRY-Bild) (Elvitegravir, Cobicistat
    PATIENT INFORMATION STRIBILD® (STRY-bild) (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) tablets Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with STRIBILD. For more information, see the section “What should I tell my healthcare provider before taking STRIBILD?” What is the most important information I should know about STRIBILD? STRIBILD can cause serious side effects, including: • Worsening of Hepatitis B infection. If you have hepatitis B virus (HBV) infection and take STRIBILD, your HBV may get worse (flare-up) if you stop taking STRIBILD. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. o Do not run out of STRIBILD. Refill your prescription or talk to your healthcare provider before your STRIBILD is all gone. o Do not stop taking STRIBILD without first talking to your healthcare provider. o If you stop taking STRIBILD, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking STRIBILD. See “What are the possible side effects of STRIBILD?” for more information about side effects. What is STRIBILD? STRIBILD is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in people 12 years of age and older: • who have not received anti-HIV-1 medicines in the past, or • to replace their current anti-HIV-1 medicines: o in people who have been on the same anti-HIV-1 medicine regimen for at least 6 months, and o who have an amount of HIV-1 in their blood (this is called “viral load”) that is less than 50 copies/mL, and o have never failed past HIV-1 treatment.
    [Show full text]
  • WO 2017/004012 Al 5 January 2017 (05.01.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/004012 Al 5 January 2017 (05.01.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/24 (2006.01) A61K 31/513 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/505 (2006.01) A61K 31/675 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 16/039762 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 28 June 2016 (28.06.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/187,102 30 June 2015 (30.06.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/296,524 17 February 2016 (17.02.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicants: GILEAD SCIENCES, INC.
    [Show full text]
  • Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
    life Communication Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B Tomoya Sano * , Takumi Kawaguchi , Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino and Takuji Torimura Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan; [email protected] (T.K.); [email protected] (T.I.); [email protected] (K.A.); [email protected] (R.K.); [email protected] (T.A.-H.); [email protected] (T.T.) * Correspondence: [email protected]; Tel.: +81-942-31-7627 Abstract: Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB. Keywords: adefovir dipivoxil (ADV); Fanconi syndrome; hepatitis B virus (HBV); renal tubular Citation: Sano, T.; Kawaguchi, T.; dysfunction; tenofovir alafenamide (TAF); tenofovir disoproxil fumarate (TDF); β2-microglobulin Ide, T.; Amano, K.; Kuwahara, R.; Arinaga-Hino, T.; Torimura, T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic 1.
    [Show full text]
  • DESCOVY, and Upon Diagnosis of These Highlights Do Not Include All the Information Needed to Use Any Other Sexually Transmitted Infections (Stis)
    HIGHLIGHTS OF PRESCRIBING INFORMATION once every 3 months while taking DESCOVY, and upon diagnosis of These highlights do not include all the information needed to use any other sexually transmitted infections (STIs). (2.2) DESCOVY safely and effectively. See full prescribing information • Recommended dosage: for DESCOVY. • Treatment of HIV-1 Infection: One tablet taken once daily with or ® without food in patients with body weight at least 25 kg. (2.3) DESCOVY (emtricitabine and tenofovir alafenamide) tablets, for • HIV-1 PrEP: One tablet taken once daily with or without food in oral use individuals with body weight at least 35 kg. (2.4) Initial U.S. Approval: 2015 • Renal impairment: DESCOVY is not recommended in individuals with WARNING: POST-TREATMENT ACUTE EXACERBATION OF estimated creatinine clearance below 30 mL per minute. (2.5) HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE ----------------------DOSAGE FORMS AND STRENGTHS--------------------­ OF DESCOVY FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS Tablets: 200 mg of FTC and 25 mg of TAF (3) (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION See full prescribing information for complete boxed warning. -------------------------------CONTRAINDICATIONS------------------------------­ DESCOVY for HIV-1 PrEP is contraindicated in individuals with Severe acute exacerbations of hepatitis B (HBV) have been unknown or positive HIV-1 status. (4) reported in HBV-infected individuals who have discontinued products containing emtricitabine (FTC) and/or tenofovir -----------------------WARNINGS AND PRECAUTIONS-----------------------­ disoproxil fumarate (TDF), and may occur with • Comprehensive management to reduce the risk of sexually discontinuation of DESCOVY. Hepatic function should be transmitted infections (STIs), including HIV-1, when DESCOVY is monitored closely in these individuals.
    [Show full text]
  • Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
    PATIENT & CAREGIVER EDUCATION Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Genvoya Brand Names: Canada Genvoya Warning Hepatitis B has gotten worse when this drug was stopped in some people with hepatitis B. Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B. Do not stop giving this drug to your child without calling your child’s doctor. Hepatitis B testing needs to be done as you were told by the doctor. Talk with the doctor. Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide 1/9 What is this drug used for? It is used to treat HIV infection. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child has any of these health problems: Kidney disease or liver disease. If your child takes any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for high cholesterol, migraines, or mood problems. There are many drugs that must not be taken with this drug. If your child is taking any other drugs to treat HIV. If your child is pregnant: Do not give this drug to your child during pregnancy.
    [Show full text]
  • EVOTAZ (Atazanavir Or Cobicistat) to Pregnant Rats and Rabbits (See Data)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Assess creatinine clearance (CLcr) before initiating treatment. Consider These highlights do not include all the information needed to use EVOTAZ alternative medications that do not require dosage adjustments in patients safely and effectively. See full prescribing information for EVOTAZ. with renal impairment. (5.3) • When cobicistat, a component of EVOTAZ, is used in combination with a EVOTAZ (atazanavir and cobicistat) tablet, for oral use tenofovir disoproxil fumarate (tenofovir DF)-containing regimen, cases of Initial U.S. Approval: 2015 acute renal failure and Fanconi syndrome have been reported. (5.4) • When used with tenofovir DF, assess urine glucose and urine protein at ---------------------------RECENT MAJOR CHANGES--------------------------­ baseline and monitor CLcr, urine glucose, and urine protein. Monitor serum Indications and Usage phosphorus in patients with or at risk for renal impairment. Coadministration Indications (1.1) 07/2020 with tenofovir DF is not recommended in patients with CLcr below 70 Dosage and Administration mL/min or in patients also receiving a nephrotoxic agent. (5.4) Laboratory Testing Prior to Initiation and During • Chronic kidney disease has been reported during postmarketing surveillance Treatment with EVOTAZ (2.1) 04/2020 in patients with HIV-1 infection treated with atazanavir, with or without Recommended Dosage (2.2) 07/2020 ritonavir. Consider alternatives in patients at high risk for renal disease or Not Recommended During Pregnancy (2.5) 04/2020 with preexisting renal disease. Monitor renal laboratory tests prior to therapy Contraindications (4) 04/2020 and during treatment with EVOTAZ. Consider discontinuation of EVOTAZ Warnings and Precautions in patients with progressive renal disease. (5.5) Immune Reconstitution Syndrome (5.11) 07/2020 • Nephrolithiasis and cholelithiasis have been reported.
    [Show full text]
  • Switching from Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
    Articles Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia T Martorell, Joseph de Wet, Hans-Jürgen Stellbrink, Jean-Michel Molina, Frank A Post, Ignacio Pérez Valero, Danielle Porter, YaPei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao Summary Background Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with Lancet HIV 2017 tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, Published Online and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability March 1, 2017 of switching to this regimen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir http://dx.doi.org/10.1016/ S2352-3018(17)30032-2 disoproxil fumarate. See Online/Articles http://dx.doi.org/10.1016/ Methods In this randomised, double-blind, placebo-controlled, non-inferiority trial, HIV-1-infected adults were S2352-3018(17)30031-0 enrolled at 120 hospitals and outpatient clinics in eight countries in North America and Europe. Participants were See Online/Comment virally suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir
    [Show full text]
  • Cobicistat + Elvitegravir + Emtricitabine + Tenofovir Alfenamide
    20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Comments on EML application : cobicistat + elvitegravir + emtricitabine + tenofovir alfenamide The WHO HIV Department does not support the addition of the formulation cobicistat + elvitegravir + emtricitabine + tenofovir alfenamide in 2017 WHO Model List of Essential Medicines for treatment of HIV infection for the following reasons Cobicisitat( COBI), elvitegravir (EVG) and tenofovir alfenamide (TAF) are not included as options in 2016 WHO consolidated guidelines on use of antiretrovirals for treating and preventing of HIV infection 1. A recent WHO systematic review comparing the use of integrase inhibitors in 1st line showed that dolutegravir and raltegravir were superior to elvitegravir/cobicistat (EVG/COBI) in terms of viral suppression, CD4 recovery and risk of treatment discontinuation.2 There are important concerns with the use of TAF and EVG/COBI in TB co-infection. EGV/COBI has important and well documented drug interactions with rifampicin and must not be co-administrated, as will result in loss of its antiviral effect3 4 Regarding TAF, there are no published data available on the pharmacokinetics and real-world efficacy of TAF in TB- coinfected patients. While the current available tenofovir prodrug (tenofovir disoproxil fumarate or TDF) does not require dose-adjustment if co-administered with rifampicin, TAF is currently contraindicated by the originator in patients being treated with rifampicin, as significant drug interaction is predicted based on pK modelling 56. Data on the potential for TAF dose adjustment are awaited. There are very limited data available on the safety of EVG/COBI and TAF during pregnancy.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]